Identification

Name
Fexofenadine
Accession Number
DB00950  (APRD00349)
Type
Small Molecule
Groups
Approved
Description

Fexofenadine hydrochloride (Allegra) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine. Fexofenadine, like other second and third-generation antihistamines, does not readily pass through the blood-brain barrier, and so causes less drowsiness than first-generation histamine-receptor antagonists.

Structure
Thumb
Synonyms
  • 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid
  • Carboxyterfenadine
  • Fexofenadine
  • Terfenadine acid metabolite
  • Terfenadine carboxylate
  • Terfenadine-COOH
Product Ingredients
IngredientUNIICASInChI Key
Fexofenadine hydrochloride2S068B75ZU153439-40-8RRJFVPUCXDGFJB-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AllegraSuspension6 mg/mLOralSanofi Aventis2006-10-16Not applicableUs
Fexofenadine HydrochlorideTablet, film coated180 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2000-02-25Not applicableUs
Fexofenadine HydrochlorideTablet, film coated60 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2000-02-25Not applicableUs66993 0107 02 nlmimage10 3a239d7c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fexofenadine HydrochlorideTablet, film coated180 mg/1OralPd Rx Pharmaceuticals, Inc.2010-05-212017-05-13Us
Fexofenadine HydrochlorideTablet, film coated180 mg/1OralAphena Pharma Solutions Tennessee, Inc.2010-07-01Not applicableUs
Fexofenadine HydrochlorideTablet, film coated180 mg/1Oralbryant ranch prepack2006-04-12Not applicableUs
Fexofenadine HydrochlorideTablet60 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2009-12-09Not applicableUs55111 0193 01 nlmimage10 f007f83f
Fexofenadine HydrochlorideTablet, film coated60 mg/1OralMajor2009-06-10Not applicableUs
Fexofenadine HydrochlorideTablet, film coated180 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2005-08-012017-02-02Us66993 0109 04 nlmimage10 6d08b6b5
Fexofenadine HydrochlorideTablet, film coated60 mg/1OralPhysicians Total Care, Inc.2006-08-07Not applicableUs
Fexofenadine HydrochlorideTablet180 mg/1OralRebel Distributors2009-12-09Not applicableUs
Fexofenadine HydrochlorideTablet60 mg/1OralRemedy Repack2011-08-222016-10-20Us
Fexofenadine HydrochlorideTablet, film coated60 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-07-01Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
24 Hour AllergyTablet180 mg/1OralLIVE BETTER (The Great Atlantic & Pacific Tea Company)2013-03-20Not applicableUs
7 Select Allergy ReliefTablet, film coated180 mg/1Oral7 Eleven2014-04-17Not applicableUs
Allegra 12 HourTablet60 mgOralSanofi Aventis1997-07-10Not applicableCanada
Allegra 24 Hour (120mg)Tablet120 mgOralSanofi Aventis2001-01-09Not applicableCanada
Allegra AllergyTablet180 mg/1OralLil' Drug Store Products, Inc.2014-09-01Not applicableUs
Allegra AllergyTablet, film coated60 mg/1OralA S Medication Solutions2011-03-032017-06-20Us
Allegra AllergyTablet, coated180 mg/1OralChattem, Inc.2014-12-17Not applicableUs
Allegra AllergyTablet, film coated180 mg/1OralChattem, Inc.2011-03-03Not applicableUs
Allegra AllergyTablet180 mg/1OralNavajo Manuracturing Company2015-05-12Not applicableUs
Allegra AllergyTablet180 mg/1OralNavajo Manuracturing Company2016-09-23Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Allergy ReliefTablet, coated180 mg/1OralCVS Health2017-10-31Not applicableUs
Fexofenadine HClTablet, film coated180 mg/1OralProficient Rx LP2015-09-16Not applicableUs
International/Other Brands
Fastofen / Fexidine / Telfast / Vifas
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Allegra D 12 Hour Allergy and CongestionFexofenadine hydrochloride (60 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, film coated, extended releaseOralRebel Distributors2011-03-03Not applicableUs
Allegra D-12 HourFexofenadine hydrochloride (60 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralPhysicians Total Care, Inc.2000-09-18Not applicableUs
Allegra D-12 HourFexofenadine hydrochloride (60 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralSanofi Aventis1997-12-24Not applicableUs00088 1090 47 nlmimage10 d503eadf
Allegra--D 24 HourFexofenadine hydrochloride (180 mg/1) + Pseudoephedrine hydrochloride (240 mg/1)Tablet, film coated, extended releaseOralPhysicians Total Care, Inc.2005-09-14Not applicableUs
Allegra--D 24 HourFexofenadine hydrochloride (180 mg/1) + Pseudoephedrine hydrochloride (240 mg/1)Tablet, film coatedOralSanofi Aventis2004-10-19Not applicableUs
Allegra-DFexofenadine hydrochloride (60 mg) + Pseudoephedrine hydrochloride (120 mg)Tablet, extended releaseOralSanofi Aventis1999-04-29Not applicableCanada
Allegra-DFexofenadine (60 mg/1) + Pseudoephedrine (60 mg/1)Tablet, extended releaseOralbryant ranch prepack2009-03-04Not applicableUs
Allegra-D 24 HourFexofenadine hydrochloride (180 mg/1) + Pseudoephedrine hydrochloride (240 mg/1)Tablet, film coatedOralStat Rx USA2004-10-19Not applicableUs
Allegra-D Allergy and CongestionFexofenadine hydrochloride (60 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, film coated, extended releaseOralA S Medication Solutions2011-03-032017-06-20Us
Allegra-D Allergy and CongestionFexofenadine hydrochloride (180 mg/1) + Pseudoephedrine hydrochloride (240 mg/1)Tablet, film coated, extended releaseOralChattem, Inc.2011-03-03Not applicableUs
Categories
UNII
E6582LOH6V
CAS number
83799-24-0
Weight
Average: 501.6564
Monoisotopic: 501.287908741
Chemical Formula
C32H39NO4
InChI Key
RWTNPBWLLIMQHL-UHFFFAOYSA-N
InChI
InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)
IUPAC Name
2-(4-{1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}phenyl)-2-methylpropanoic acid
SMILES
CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication

For management of Seasonal allergic rhinitis

Structured Indications
Pharmacodynamics

Fexofenadine is a second-generation, long lasting H1-receptor antagonist (antihistamine) which has a selective and peripheral H1-antagonist action. Histamine is a chemical that causes many of the signs that are part of allergic reactions, such as the swelling of tissues. Histamine is released from histamine-storing cells (mast cells) and attaches to other cells that have receptors for histamine. The attachment of the histamine to the receptors causes the cell to be "activated," releasing other chemicals which produce the effects that we associate with allergy. Fexofenadine blocks one type of receptor for histamine (the H1 receptor) and thus prevents activation of cells by histamine. Unlike most other antihistamines, Fexofenadine does not enter the brain from the blood and, therefore, does not cause drowsiness. Fexofenadine lacks the cardiotoxic potential of terfenadine, since it does not block the potassium channel involved in repolarization of cardiac cells.

Mechanism of action

Like other H1-blockers, Fexofenadine competes with free histamine for binding at H1-receptors in the GI tract, large blood vessels, and bronchial smooth muscle. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine. Fexofenadine exhibits no anticholinergic, antidopaminergic, alpha1-adrenergic or beta-adrenergic-receptor blocking effects.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
Absorption

33%

Volume of distribution
Not Available
Protein binding

60%-70%

Metabolism

Approximately 5% of the total dose is metabolized, by cytochrome P450 3A4 and by intestinal microflora.

Route of elimination
Not Available
Half life

14.4 hours

Clearance
Not Available
Toxicity

Side effects include dizziness, drowsiness, and dry mouth.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Fexofenadine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Fexofenadine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Fexofenadine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Fexofenadine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fexofenadine.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fexofenadine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fexofenadine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Fexofenadine.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Fexofenadine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fexofenadine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Fexofenadine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Fexofenadine.Approved, Illicit
AlgeldrateThe serum concentration of Fexofenadine can be decreased when it is combined with Algeldrate.Approved, Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Fexofenadine.Investigational
AlmagateThe serum concentration of Fexofenadine can be decreased when it is combined with Almagate.Experimental
AlmasilateThe serum concentration of Fexofenadine can be decreased when it is combined with Almasilate.Approved, Experimental
AloglutamolThe serum concentration of Fexofenadine can be decreased when it is combined with Aloglutamol.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Fexofenadine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Fexofenadine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fexofenadine.Approved, Illicit, Investigational
AluminiumThe serum concentration of Fexofenadine can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Fexofenadine can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Fexofenadine can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Fexofenadine can be decreased when it is combined with Aluminum hydroxide.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fexofenadine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fexofenadine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fexofenadine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fexofenadine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Fexofenadine.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Fexofenadine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fexofenadine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Fexofenadine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Fexofenadine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Fexofenadine.Investigational, Vet Approved
AzelastineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Fexofenadine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Fexofenadine.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Fexofenadine.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fexofenadine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Fexofenadine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Fexofenadine.Approved
Benzylpenicilloyl PolylysineFexofenadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Fexofenadine.Approved
Bismuth SubcitrateThe serum concentration of Fexofenadine can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Fexofenadine can be decreased when it is combined with Bismuth subnitrate.Experimental
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Fexofenadine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fexofenadine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fexofenadine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Fexofenadine.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Fexofenadine.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Fexofenadine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Fexofenadine.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fexofenadine.Approved, Investigational
BuprenorphineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fexofenadine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fexofenadine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Fexofenadine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Fexofenadine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Fexofenadine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Fexofenadine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fexofenadine.Approved, Illicit, Vet Approved
Calcium CarbonateThe serum concentration of Fexofenadine can be decreased when it is combined with Calcium Carbonate.Approved
Calcium silicateThe serum concentration of Fexofenadine can be decreased when it is combined with Calcium silicate.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Fexofenadine.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fexofenadine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Fexofenadine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Fexofenadine.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fexofenadine.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fexofenadine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fexofenadine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fexofenadine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Fexofenadine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fexofenadine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Fexofenadine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fexofenadine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fexofenadine.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fexofenadine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fexofenadine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Fexofenadine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Fexofenadine.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Fexofenadine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Fexofenadine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Fexofenadine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Fexofenadine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fexofenadine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Fexofenadine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fexofenadine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fexofenadine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Fexofenadine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Fexofenadine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fexofenadine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Fexofenadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fexofenadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fexofenadine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Fexofenadine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fexofenadine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Fexofenadine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fexofenadine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fexofenadine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Fexofenadine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fexofenadine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fexofenadine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Fexofenadine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Fexofenadine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Fexofenadine.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Fexofenadine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fexofenadine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fexofenadine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fexofenadine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fexofenadine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fexofenadine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Fexofenadine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Fexofenadine.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Fexofenadine.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Fexofenadine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Fexofenadine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fexofenadine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Fexofenadine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Fexofenadine.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Fexofenadine.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Fexofenadine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Fexofenadine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fexofenadine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Fexofenadine.Approved, Investigational
ErythromycinThe serum concentration of Fexofenadine can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Fexofenadine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fexofenadine.Approved
EthanolFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fexofenadine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fexofenadine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fexofenadine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fexofenadine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Fexofenadine.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fexofenadine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fexofenadine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Fexofenadine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Fexofenadine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Fexofenadine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fexofenadine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Fexofenadine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Fexofenadine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Fexofenadine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fexofenadine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fexofenadine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Fexofenadine.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fexofenadine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fexofenadine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fexofenadine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fexofenadine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fexofenadine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fexofenadine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fexofenadine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fexofenadine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Fexofenadine.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fexofenadine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fexofenadine.Approved, Illicit, Investigational
GepefrineGepefrine may decrease the sedative activities of Fexofenadine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Fexofenadine.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Fexofenadine.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fexofenadine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fexofenadine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Fexofenadine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Fexofenadine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fexofenadine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fexofenadine.Approved, Investigational
HydrocodoneFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fexofenadine.Approved, Illicit
HydrotalciteThe serum concentration of Fexofenadine can be decreased when it is combined with Hydrotalcite.Experimental, Investigational
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Fexofenadine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fexofenadine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Fexofenadine.Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Fexofenadine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fexofenadine.Approved, Vet Approved
ItraconazoleThe serum concentration of Fexofenadine can be increased when it is combined with Itraconazole.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fexofenadine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fexofenadine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Fexofenadine.Approved, Investigational
KetoconazoleThe serum concentration of Fexofenadine can be increased when it is combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fexofenadine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Fexofenadine.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fexofenadine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fexofenadine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fexofenadine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fexofenadine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Fexofenadine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Fexofenadine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Fexofenadine.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Fexofenadine.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Fexofenadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fexofenadine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Fexofenadine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fexofenadine.Approved
LumacaftorThe serum concentration of Fexofenadine can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fexofenadine.Approved
MagaldrateThe serum concentration of Fexofenadine can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe serum concentration of Fexofenadine can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Fexofenadine can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Fexofenadine can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Fexofenadine can be decreased when it is combined with Magnesium silicate.Approved, Experimental
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved, Vet Approved
Magnesium TrisilicateThe serum concentration of Fexofenadine can be decreased when it is combined with Magnesium Trisilicate.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fexofenadine.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Fexofenadine.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Fexofenadine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Fexofenadine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Fexofenadine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Fexofenadine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Fexofenadine.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Fexofenadine.Investigational
MephentermineMephentermine may decrease the sedative activities of Fexofenadine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fexofenadine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fexofenadine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Fexofenadine.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fexofenadine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fexofenadine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Fexofenadine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Fexofenadine.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Fexofenadine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fexofenadine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fexofenadine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fexofenadine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fexofenadine.Approved
MethotrimeprazineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fexofenadine.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Fexofenadine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Fexofenadine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fexofenadine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Fexofenadine.Approved, Investigational
MetyrosineFexofenadine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fexofenadine.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative activities of Fexofenadine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved, Investigational
MirtazapineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may decrease the sedative activities of Fexofenadine.Experimental, Illicit
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Fexofenadine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fexofenadine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fexofenadine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Fexofenadine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fexofenadine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Fexofenadine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Fexofenadine.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Fexofenadine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fexofenadine.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fexofenadine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fexofenadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fexofenadine.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Fexofenadine.Approved, Illicit
OrphenadrineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Fexofenadine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fexofenadine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Fexofenadine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fexofenadine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fexofenadine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fexofenadine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fexofenadine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fexofenadine.Approved
ParaldehydeFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Fexofenadine.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Fexofenadine.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fexofenadine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fexofenadine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Fexofenadine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Fexofenadine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fexofenadine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fexofenadine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Fexofenadine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Fexofenadine.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fexofenadine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Fexofenadine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Fexofenadine.Approved
PhenterminePhentermine may decrease the sedative activities of Fexofenadine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Fexofenadine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Fexofenadine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fexofenadine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Fexofenadine.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Pomalidomide.Approved
PramipexoleFexofenadine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Fexofenadine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Fexofenadine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fexofenadine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fexofenadine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Fexofenadine.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fexofenadine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fexofenadine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Fexofenadine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Fexofenadine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fexofenadine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fexofenadine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Fexofenadine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fexofenadine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Fexofenadine.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Fexofenadine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Fexofenadine.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Fexofenadine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Fexofenadine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fexofenadine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Fexofenadine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Fexofenadine.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Ramelteon.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Fexofenadine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fexofenadine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fexofenadine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fexofenadine.Approved, Investigational
RifampicinThe serum concentration of Fexofenadine can be decreased when it is combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Fexofenadine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fexofenadine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Fexofenadine.Investigational
RitobegronRitobegron may decrease the sedative activities of Fexofenadine.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Fexofenadine.Vet Approved
RopiniroleFexofenadine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fexofenadine.Approved
RotigotineFexofenadine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fexofenadine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fexofenadine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fexofenadine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Fexofenadine.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Fexofenadine.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fexofenadine.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Fexofenadine.Approved
Sodium bicarbonateThe serum concentration of Fexofenadine can be decreased when it is combined with Sodium bicarbonate.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fexofenadine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fexofenadine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Fexofenadine.Experimental
SuvorexantFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Fexofenadine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fexofenadine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Fexofenadine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Fexofenadine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Fexofenadine.Investigational
ThalidomideFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fexofenadine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fexofenadine.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Fexofenadine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fexofenadine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Fexofenadine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Fexofenadine.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Fexofenadine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Fexofenadine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fexofenadine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fexofenadine.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Fexofenadine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Fexofenadine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fexofenadine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fexofenadine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fexofenadine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Fexofenadine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fexofenadine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Fexofenadine.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Fexofenadine.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fexofenadine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Fexofenadine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fexofenadine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fexofenadine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fexofenadine.Approved
TromethamineThe serum concentration of Fexofenadine can be decreased when it is combined with Tromethamine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fexofenadine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Fexofenadine.Experimental
VerapamilThe bioavailability of Fexofenadine can be increased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Vigabatrin.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Fexofenadine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Fexofenadine.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Fexofenadine.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Fexofenadine.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Fexofenadine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fexofenadine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fexofenadine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Fexofenadine.Vet Approved
ZolpidemFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fexofenadine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Fexofenadine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Fexofenadine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fexofenadine.Approved, Investigational
Food Interactions
  • Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can significantly decrease serum levels of this product.
  • Take without regard to meals.

References

Synthesis Reference

Federico Milla, "Processes for the production of fexofenadine." U.S. Patent US20030166682, issued September 04, 2003.

US20030166682
General References
  1. Smith SM, Gums JG: Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):813-22. doi: 10.1517/17425250903044967. [PubMed:19545214]
  2. Bachert C: A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin Ther. 2009 May;31(5):921-44. doi: 10.1016/j.clinthera.2009.05.017. [PubMed:19539095]
  3. Markham A, Wagstaff AJ: Fexofenadine. Drugs. 1998 Feb;55(2):269-74; discussion 275-6. [PubMed:9506246]
  4. Golightly LK, Greos LS: Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs. 2005;65(3):341-84. [PubMed:15669879]
  5. Molimard M, Diquet B, Benedetti MS: Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol. 2004 Aug;18(4):399-411. [PubMed:15312146]
External Links
Human Metabolome Database
HMDB05030
KEGG Compound
C06999
PubChem Compound
3348
PubChem Substance
46504676
ChemSpider
3231
BindingDB
22874
ChEBI
5050
ChEMBL
CHEMBL914
Therapeutic Targets Database
DAP000330
PharmGKB
PA449621
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Fexofenadine
ATC Codes
R06AX26 — Fexofenadine
AHFS Codes
  • 04:08.00 — Second Generation Antihistamines
FDA label
Download (43.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedNot AvailableHealthy Volunteers5
1CompletedBasic ScienceAdministration, Oral / Magnetic Resonance Imaging (MRI) / Pharmacokinetics1
1CompletedDiagnosticDrug Interactions1
1CompletedDiagnosticHealthy Volunteers1
1CompletedTreatmentAllergic Rhinitis (AR)1
1CompletedTreatmentDrug Interaction Potentiation1
1CompletedTreatmentDrug Interactions1
1CompletedTreatmentHealthy Volunteers5
1RecruitingBasic ScienceChronic Obstructive Pulmonary Disease (COPD) / Heart Failure, Unspecified / Hypertensive / Pulmonary Arterial Hypertension (PAH)1
1TerminatedTreatmentHealthy Volunteers1
2CompletedSupportive CareItching1
2CompletedTreatmentAllergic Rhinitis (AR)2
2CompletedTreatmentEdema1
2CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
2, 3CompletedTreatmentAtopic Dermatitis (AD)1
2, 3CompletedTreatmentRhinitis Perennial1
3CompletedTreatmentAsthma Bronchial2
3CompletedTreatmentPerennial Allergic Rhinitis (PAR)1
3CompletedTreatmentSeasonal Rhinitis1
4CompletedNot AvailableSeasonal Allergic Rhinitis (SAR)2
4CompletedOtherSeasonal Allergic Rhinitis (SAR)1
4CompletedTreatmentAllergic Rhinitis (AR)5
4CompletedTreatmentCat Induced Allergic Rhinitis1
4CompletedTreatmentPruritus1
4CompletedTreatmentRhinitis1
4CompletedTreatmentRhinitis, Allergic, Perennial1
4CompletedTreatmentRhinitis, Allergic, Seasonal2
4CompletedTreatmentSeasonal Allergic Rhinitis (SAR)4
4CompletedTreatmentUrticarias1
4Not Yet RecruitingBasic ScienceHemodialysis-dependent patients1
4Unknown StatusTreatmentUremic Pruritus1
Not AvailableCompletedNot AvailableFood-Drug Interactions1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableRecruitingNot AvailableDepression1

Pharmacoeconomics

Manufacturers
  • Sanofi aventis us llc
  • Barr laboratories inc
  • Dr reddys laboratories ltd
  • Mylan pharmaceuticals inc
  • Teva pharmaceuticals usa inc
  • Sanofi-Aventis
Packagers
Dosage forms
FormRouteStrength
TabletOral60 mg
TabletOral120 mg
Tablet, coatedOral180 mg/1
Tablet, film coatedOral
SuspensionOral6 mg/mL
Tablet, orally disintegratingOral30 mg/1
SuspensionOral30 mg/5mL
Tablet, film coatedOral180 mg/1
Tablet, film coatedOral60 mg/1
TabletOral180 mg/1
Tablet, extended releaseOral
TabletOral60 mg/1
Tablet, film coatedOral30 mg/1
Tablet, film coated, extended releaseOral
Prices
Unit descriptionCostUnit
Allegra ODT 60 30 mg Dispersible Tablet Box126.0USD box
Allegra-D 24 Hour 180-240 mg 24 Hour tablet5.01USD tablet
Allegra-d 24 hour tablet4.98USD tablet
Allegra 180 mg tablet2.89USD tablet
Allegra-D 12 Hour 60-120 mg 12 Hour tablet2.72USD tablet
Allegra-d 12 hour tablet2.49USD tablet
Fexofenadine hcl 180 mg tablet2.47USD tablet
Allegra odt 30 mg tablet1.98USD tablet
Allegra 60 mg tablet1.64USD tablet
Fexofenadine hcl 60 mg tablet1.43USD tablet
Allegra 30 mg tablet0.81USD tablet
Fexofenadine hcl 30 mg tablet0.71USD tablet
Allegra 30 mg/5ml Suspension0.25USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5178878No1993-01-122010-01-12Us
CA2301267No2004-07-132018-07-21Canada
CA2134211No1999-06-292013-04-06Canada
US6037353Yes1997-09-142017-09-14Us
US6039974No1998-07-312018-07-31Us
US6723348No2001-11-262021-11-26Us
US6613357No2000-12-252020-12-25Us
USRE39069No1998-05-292018-05-29Us
US8933097No2012-08-162032-08-16Us
US6113942Yes1995-08-282015-08-28Us
US5855912Yes1995-08-282015-08-28Us
US5932247Yes1995-08-282015-08-28Us
US5738872Yes1995-08-282015-08-28Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)142.5 °CPhysProp
water solubilitySlightly solubleNot Available
logP5.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00266 mg/mLALOGPS
logP5.02ALOGPS
logP2.94ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)4.04ChemAxon
pKa (Strongest Basic)9.01ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area81 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity147.98 m3·mol-1ChemAxon
Polarizability57.42 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7881
Blood Brain Barrier-0.8574
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.8641
P-glycoprotein inhibitor INon-inhibitor0.6791
P-glycoprotein inhibitor IINon-inhibitor0.8779
Renal organic cation transporterNon-inhibitor0.5166
CYP450 2C9 substrateNon-substrate0.836
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6458
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9162
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8421
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9756
Ames testNon AMES toxic0.9122
CarcinogenicityNon-carcinogens0.9163
BiodegradationNot ready biodegradable0.8428
Rat acute toxicity2.3481 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8469
hERG inhibition (predictor II)Inhibitor0.6258
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a6r-0005900000-17ae091cc3d9ba9c62f3
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a6r-0396000000-be2d6fedab983b50c280
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-1970000000-c78b1c745afc54f58e01
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4r-0920000000-9ad3dc88e743866c23ca
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0btj-0900000000-66a31911b29382b93745
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-1900000000-ce2d00bbddc284806cb0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0000090000-2622c1f2ddb4bff3f93d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0159-0000910000-0afa1079fbe9a822e35c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00xr-1920200000-1163d721ce08480aea71
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-1910000000-c593678096415da5efb2
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-002f-2900000000-01de1f32826ab5569301
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-002f-3900000000-72f624b2d6e05d29cb72

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Phenylbutylamines / Phenylpropanes / Aralkylamines / Piperidines / Tertiary alcohols / Trialkylamines / Secondary alcohols / Amino acids / Monocarboxylic acids and derivatives / Azacyclic compounds
show 6 more
Substituents
Diphenylmethane / Phenylbutylamine / Phenylpropane / Aralkylamine / Piperidine / Tertiary alcohol / Amino acid or derivatives / Secondary alcohol / Amino acid / Tertiary amine
show 18 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
piperidines, tertiary amine (CHEBI:5050)

Targets

Details
1. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Amon U, Amon S, Gibbs BF: In vitro studies with fexofenadine, a new nonsedating histamine H1 receptor antagonist, on isolated human basophils. Inflamm Res. 2000 Apr;49 Suppl 1:S13-4. [PubMed:10864400]
  3. Abbas MN, Abdel Fattah AA, Zahran E: A novel membrane sensor for histamine H1-receptor antagonist "fexofenadine". Anal Sci. 2004 Aug;20(8):1137-42. [PubMed:15352500]
  4. Grzelewska-Rzymowska I, Kroczynska-Bednarek J, Pietrzkowicz M: [Effect of fexofenadine--selective antagonist of histamine receptor (H1) on histamine-induced bronchoconstriction]. Pol Merkur Lekarski. 2003 Jan;14(79):43-6. [PubMed:12712828]
  5. Tashiro M, Sakurada Y, Iwabuchi K, Mochizuki H, Kato M, Aoki M, Funaki Y, Itoh M, Iwata R, Wong DF, Yanai K: Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol. 2004 Aug;44(8):890-900. [PubMed:15286093]
  6. Cavero I, Mestre M, Guillon JM, Heuillet E, Roach AG: Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans? Drug Saf. 1999;21 Suppl 1:19-31; discussion 81-7. [PubMed:10597865]
  7. Devillier P, Roche N, Faisy C: Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30. [PubMed:18336052]
  8. Dhanya NB, Thasleem Z, Rai R, Srinivas CR: Comparative efficacy of levocetirizine, desloratidine and fexofenadine by histamine wheal suppression test. Indian J Dermatol Venereol Leprol. 2008 Jul-Aug;74(4):361-3. [PubMed:18797058]
  9. Smith SM, Gums JG: Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):813-22. doi: 10.1517/17425250903044967. [PubMed:19545214]
  10. Markham A, Wagstaff AJ: Fexofenadine. Drugs. 1998 Feb;55(2):269-74; discussion 275-6. [PubMed:9506246]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612]
  2. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ: Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res. 1999 Apr;16(4):478-85. [PubMed:10227700]
  3. Petri N, Tannergren C, Rungstad D, Lennernas H: Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res. 2004 Aug;21(8):1398-404. [PubMed:15359574]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45. Epub 2003 Nov 10. [PubMed:14610227]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H, Sugiyama Y: Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos. 2005 Oct;33(10):1477-81. Epub 2005 Jul 13. [PubMed:16014768]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:33